Risk of Gastrointestinal Events During Lapatinib Therapy: A Meta-Analysis From 12,402 Patients With Cancer
Sign Up to like & getrecommendations! Published in 2018 at "American Journal of Therapeutics"
DOI: 10.1097/mjt.0000000000000368
Abstract: Lapatinib, a tyrosine kinase inhibitor used as an anticancer therapeutic agent, has adverse events associated with treatment resulting in noncompliance and withdrawal from the therapy. Here, we performed meta-analysis of published clinical trials to determine… read more here.
Keywords: risk; therapy; patients cancer; gastrointestinal events ... See more keywords
Development and internal validation of a risk scoring system for gastrointestinal events requiring surgery in gastrointestinal lymphoma patients
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Gastroenterology and Hepatology"
DOI: 10.1111/jgh.14452
Abstract: The predictors of severe gastrointestinal (GI) events in GI lymphoma patients are unclear. We aimed to develop a risk scoring system for GI events requiring surgery. read more here.
Keywords: events requiring; scoring system; risk scoring; lymphoma patients ... See more keywords
Incidence and mitigation of gastrointestinal events in patients with relapsing–remitting multiple sclerosis receiving delayed-release dimethyl fumarate: a German phase IV study (TOLERATE)
Sign Up to like & getrecommendations! Published in 2018 at "Therapeutic Advances in Neurological Disorders"
DOI: 10.1177/1756286418768775
Abstract: Background: Gastrointestinal (GI) events are common adverse events (AEs) associated with delayed-release dimethyl fumarate (DMF), an approved treatment for relapsing–remitting multiple sclerosis (RRMS). The objective of the TOLERATE study was to evaluate GI tolerability and… read more here.
Keywords: study; mitigation; gastrointestinal events; delayed release ... See more keywords